Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APGE Apogee Therapeutics	$37.29 -2.2%	$40.09	$26.20 ▼ $63.50	$1.76B	1.43	614,452 shs	552,735 shs
DYN Dyne Therapeutics	$12.38 -1.0%	$10.46	$6.36 ▼ $47.45	$1.78B	1.08	2.97 million shs	1.93 million shs
IMCR Immunocore	$32.88 -0.5%	$33.60	$23.15 ▼ $39.33	$1.66B	0.77	327,356 shs	180,187 shs
PFNX Pfenex	$12.75	$12.75	$5.26 ▼ $14.00	$437.29M	N/A	503,865 shs	N/A

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APGE Apogee Therapeutics	-2.18%	+5.37%	-2.81%	-8.20%	-15.69%
DYN Dyne Therapeutics	-0.96%	+10.93%	+32.69%	+4.65%	-71.79%
IMCR Immunocore	-0.54%	+2.85%	-8.00%	+8.26%	-11.06%
PFNX Pfenex	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APGE Apogee Therapeutics	3.0332 of 5 stars	3.5	3.0	0.0	0.0	2.2	4.2	0.0
DYN Dyne Therapeutics	3.3545 of 5 stars	4.5	1.0	0.0	0.0	2.5	4.2	0.0
IMCR Immunocore	1.9354 of 5 stars	3.3	1.0	0.0	0.0	2.7	2.5	0.0
PFNX Pfenex	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APGE Apogee Therapeutics	3.00	Buy	$99.00	165.49% Upside
DYN Dyne Therapeutics	3.00	Buy	$33.80	173.02% Upside
IMCR Immunocore	2.50	Moderate Buy	$58.00	76.40% Upside
PFNX Pfenex	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest PFNX, APGE, DYN, and IMCR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2025	APGE Apogee Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$90.00
8/6/2025	DYN Dyne Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$34.00 ➝ $13.00
7/31/2025	DYN Dyne Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$66.00 ➝ $36.00
7/29/2025	DYN Dyne Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$25.00 ➝ $23.00
7/29/2025	DYN Dyne Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$37.00 ➝ $31.00
7/29/2025	DYN Dyne Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$50.00 ➝ $38.00
7/15/2025	DYN Dyne Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$10.00 ➝ $9.00
7/11/2025	DYN Dyne Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
7/7/2025	APGE Apogee Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
7/7/2025	APGE Apogee Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$90.00
7/7/2025	APGE Apogee Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$100.00 ➝ $115.00

(Data available from 8/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	$13.43 per share	N/A
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	$4.02 per share	N/A
IMCR Immunocore	$310.20M	5.32	N/A	N/A	$7.73 per share	4.25
PFNX Pfenex	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APGE Apogee Therapeutics	-$182.15M	-$4.13	N/A	N/A	N/A	N/A	-34.65%	-32.76%	N/A
DYN Dyne Therapeutics	-$317.42M	-$3.86	N/A	N/A	N/A	N/A	-64.12%	-56.75%	N/A
IMCR Immunocore	-$51.09M	-$0.40	N/A	N/A	N/A	-5.70%	-5.40%	-1.93%	N/A
PFNX Pfenex	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest PFNX, APGE, DYN, and IMCR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	APGE Apogee Therapeutics	-$1.03	-$1.13	-$0.10	-$1.13	N/A	N/A
8/7/2025	Q2 2025	IMCR Immunocore	-$0.21	-$0.20	+$0.01	-$0.20	$122.96 million	$130.65 million
7/28/2025	Q2 2025	DYN Dyne Therapeutics	-$0.99	-$0.97	+$0.02	-$0.97	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	N/A
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	N/A
IMCR Immunocore	N/A	N/A	N/A	N/A	N/A
PFNX Pfenex	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APGE Apogee Therapeutics	N/A	16.36	15.82
DYN Dyne Therapeutics	0.17	16.83	16.83
IMCR Immunocore	1.01	5.89	5.86
PFNX Pfenex	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APGE Apogee Therapeutics	79.04%
DYN Dyne Therapeutics	96.68%
IMCR Immunocore	84.50%
PFNX Pfenex	N/A

Insider Ownership

Company	Insider Ownership
APGE Apogee Therapeutics	42.77%
DYN Dyne Therapeutics	14.14%
IMCR Immunocore	10.40%
PFNX Pfenex	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APGE Apogee Therapeutics	91	46.11 million	26.39 million	Optionable
DYN Dyne Therapeutics	100	142.26 million	122.15 million	Optionable
IMCR Immunocore	320	50.23 million	45.01 million	Optionable
PFNX Pfenex	71	34.30 million	N/A	Not Optionable

PFNX, APGE, DYN, and IMCR Headlines

Recent News About These Companies

UCB posts more supportive data from Humira rival bimekizumab

November 6, 2024 | pharmaphorum.comP

NKY Medical Holdings Ltd Class A 300109

January 31, 2024 | morningstar.comM

Last available seats at PFS West Coast Conference next week

May 19, 2023 | pharmaphorum.comP

Ligand Pharmaceuticals and Playa Hotels Resorts Exceed Q1 ... - Best Stocks

May 4, 2023 | news.google.comN

150+ Active Companies working to develop 160+ Pipeline ... - Digital Journal

April 12, 2023 | news.google.comN

Here's Why You Should Add Ligand (LGND) Stock to Your Portfolio - Nasdaq

April 6, 2023 | news.google.comN

LENZ Therapeutics Closes $83.5M Series B - San Diego Business Journal

March 29, 2023 | news.google.comN

Ranibizumab Biosimilars Report 2023: Therapies and Ranibizumab ... - Digital Journal

March 17, 2023 | news.google.comN

Global Inflammatory Bowel Disease (IBD) Therapeutics Market to ... - GlobeNewswire

March 15, 2023 | news.google.comN

San Diego's Lenz Therapeutics snags $83.5M for once-a-day eye ... - The San Diego Union-Tribune

March 15, 2023 | news.google.comN

Osteoporosis Treatment research scope: In-depth Growth Analysis ... - Digital Journal

March 13, 2023 | news.google.comN

Current and Future Analysis of Osteoporosis Treatment Market With New Business Strategies and Forecast by 2030 - openPR

March 1, 2023 | news.google.comN

Ligand Reports Fourth Quarter and Full Year 2022 Financial Results - The Bakersfield Californian

February 23, 2023 | news.google.comN

Ligand Reports Fourth Quarter and Full Year 2022 Financial Results - Business Wire

February 22, 2023 | news.google.comN

February 8, 2023 | news.google.comN

Osteoporosis Treatment Market Set to Witness Explosive Growth By ... - Digital Journal

February 7, 2023 | news.google.comN

Injectable Drug Delivery Market Dynamic Demand, Growth ... - PharmiWeb.com

January 27, 2023 | news.google.comN

Osteoporosis Treatment Market Research Scope: In-Depth Growth ... - Digital Journal

January 27, 2023 | news.google.comN

Injectable Drug Delivery Market 2023 Segmentation and Regional Analysis by 2032 - openPR

January 6, 2023 | news.google.comN

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

PFNX, APGE, DYN, and IMCR Company Descriptions

Apogee Therapeutics NASDAQ:APGE

$37.29 -0.83 (-2.18%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$37.44 +0.15 (+0.40%)

As of 08/15/2025 07:58 PM Eastern

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

Dyne Therapeutics NASDAQ:DYN

$12.38 -0.12 (-0.96%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$12.38 -0.01 (-0.04%)

As of 08/15/2025 05:32 PM Eastern

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Immunocore NASDAQ:IMCR

$32.88 -0.18 (-0.54%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$32.96 +0.08 (+0.24%)

As of 08/15/2025 04:16 PM Eastern

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Pfenex NYSEAMERICAN:PFNX

$12.75 0.00 (0.00%)

As of 10/1/2020

Pfenex Inc., a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study. The company also develops PF582, a biosimilar candidate to Lucentis; PF529, a biosimilar to Neulasta; and hematology/oncology products, including PF743, a recombinant crisantaspase, as well as PF745, a recombinant crisantaspase with half-life extension technology. In addition, it has license and supply agreements for CRM197, a non-toxic mutant of diphtheria toxin. Pfenex Inc. is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time